GeNeuro develops a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA.

Products, services, technology

GeNeuro has developed temelimab, a humanized monoclonal antibody targeting pHERV-W Env. Temelimab has proven in the Phase II CHANGE-MS 270-patient trial, and in its ANGEL-MS extension, to have a coherent impact across all key markers associated with disease progression in multiple sclerosis.

Location
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2006
  • Number of employees in Switzerland
    20-49
Key business